RxDoctor Payments Data

Alyson Hommel, MD

Neuromuscular Medicine · Wilmington, NCNPI 1649591066

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $50,855 of the $76,201 with a category attached, or 66.7%. 9 manufacturers reported payments, led by Argenx US, Inc. at 56.0% of the total.

$76,201in general payments, 2019–2025

Across 120 payments — averaging $635.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$43K
  • UCB, Inc.$26K
  • Amgen$6K
  • AstraZeneca$497
  • Bristol Myers Squibb$43
  • Alnylam Pharmaceuticals Inc.$42
  • plus $43 from 3 others

What the payments were for

  • Consulting fees$15,66421%
  • Speaking & faculty fees$50,85567%
  • Travel & lodging$6,6689%
  • Food & beverage$2,7574%
  • Education$2560%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$134,800
Medicare patients
258
Services billed
4,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc24$1,397,647
Gamunex-CImmune Globul G/Gly/Iga Avg 4697$590,627
GammakedImmune Globul G/Gly/Iga Avg 4623$463,983
OctagamImmun Globg(Igg)/Malt/Iga Ov5023$258,938
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5034$130,915
Mycophenolate Mofetil44$7,925
Memantine Hcl83$3,792
Pyridostigmine Bromide63$3,784
Rasagiline Mesylate27$2,905
Gabapentin130$2,412
Pregabalin88$1,880
Carbamazepine ErCarbamazepine14$1,769
Donepezil Hcl45$1,755
Azathioprine15$1,517
Carbidopa-LevodopaCarbidopa/Levodopa52$879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart Hytrulo$42,671$1,397,64724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →